Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion

H. C. Diener; R. Bernstein; K. Butcher; B. Campbell; G. Cloud; A. Davalos; S. Davis; J. M. Ferro; M. Grond; D. Krieger; G. Ntaios; A. Slowik; E. Touzé

doi:10.1177/1747493016669849

Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion

H. C. Diener, R. Bernstein, K. Butcher, B. Campbell, G. Cloud, A. Davalos, S. Davis, J. M. Ferro, M. Grond, D. Krieger, G. Ntaios, A. Slowik, E. Touzé

Department of Medicine

Research output: Contribution to journal › Article › Research › peer-review

51 Citations (Scopus)

Abstract

© 2016, © 2016 World Stroke Organization. Systemic thrombolysis with rt-PA is contraindicated in patients with acute ischemic stroke anticoagulated with dabigatran. This expert opinion provides guidance on the use of the specific reversal agent idarucizumab followed by rt-PA and/or thrombectomy in patients with ischemic stroke pre-treated with dabigatran. The use of idarucizumab followed by rt-PA is covered by the label of both drugs.

Original language	English
Pages (from-to)	9-12
Journal	International Journal of Stroke
Volume	12
Issue number	1
DOIs	https://doi.org/10.1177/1747493016669849
Publication status	Published - 1 Jan 2017

Keywords

dabigatran
idarucizumab
Ischemic stroke
rt-PA
thrombectomy
thrombolysis

Access to Document

10.1177/1747493016669849

Cite this

Diener, H. C., Bernstein, R., Butcher, K., Campbell, B., Cloud, G., Davalos, A., Davis, S., Ferro, J. M., Grond, M., Krieger, D., Ntaios, G., Slowik, A., & Touzé, E. (2017). Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion. International Journal of Stroke, 12(1), 9-12. https://doi.org/10.1177/1747493016669849

@article{917374c1e81049dbafe8e23eac65a849,

title = "Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion",

abstract = "{\textcopyright} 2016, {\textcopyright} 2016 World Stroke Organization. Systemic thrombolysis with rt-PA is contraindicated in patients with acute ischemic stroke anticoagulated with dabigatran. This expert opinion provides guidance on the use of the specific reversal agent idarucizumab followed by rt-PA and/or thrombectomy in patients with ischemic stroke pre-treated with dabigatran. The use of idarucizumab followed by rt-PA is covered by the label of both drugs.",

keywords = "dabigatran, idarucizumab, Ischemic stroke, rt-PA, thrombectomy, thrombolysis",

author = "Diener, {H. C.} and R. Bernstein and K. Butcher and B. Campbell and G. Cloud and A. Davalos and S. Davis and Ferro, {J. M.} and M. Grond and D. Krieger and G. Ntaios and A. Slowik and E. Touz{\'e}",

year = "2017",

month = jan,

day = "1",

doi = "10.1177/1747493016669849",

language = "English",

volume = "12",

pages = "9--12",

journal = "International Journal of Stroke",

issn = "1747-4930",

publisher = "SAGE Publications Ltd",

number = "1",

}

Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion. / Diener, H. C.; Bernstein, R.; Butcher, K.; Campbell, B.; Cloud, G.; Davalos, A.; Davis, S.; Ferro, J. M.; Grond, M.; Krieger, D.; Ntaios, G.; Slowik, A.; Touzé, E.

In: International Journal of Stroke, Vol. 12, No. 1, 01.01.2017, p. 9-12.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion

AU - Diener, H. C.

AU - Bernstein, R.

AU - Butcher, K.

AU - Campbell, B.

AU - Cloud, G.

AU - Davalos, A.

AU - Davis, S.

AU - Ferro, J. M.

AU - Grond, M.

AU - Krieger, D.

AU - Ntaios, G.

AU - Slowik, A.

AU - Touzé, E.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - © 2016, © 2016 World Stroke Organization. Systemic thrombolysis with rt-PA is contraindicated in patients with acute ischemic stroke anticoagulated with dabigatran. This expert opinion provides guidance on the use of the specific reversal agent idarucizumab followed by rt-PA and/or thrombectomy in patients with ischemic stroke pre-treated with dabigatran. The use of idarucizumab followed by rt-PA is covered by the label of both drugs.

AB - © 2016, © 2016 World Stroke Organization. Systemic thrombolysis with rt-PA is contraindicated in patients with acute ischemic stroke anticoagulated with dabigatran. This expert opinion provides guidance on the use of the specific reversal agent idarucizumab followed by rt-PA and/or thrombectomy in patients with ischemic stroke pre-treated with dabigatran. The use of idarucizumab followed by rt-PA is covered by the label of both drugs.

KW - dabigatran

KW - idarucizumab

KW - Ischemic stroke

KW - rt-PA

KW - thrombectomy

KW - thrombolysis

U2 - 10.1177/1747493016669849

DO - 10.1177/1747493016669849

M3 - Article

VL - 12

SP - 9

EP - 12

JO - International Journal of Stroke

JF - International Journal of Stroke

SN - 1747-4930

IS - 1

ER -

Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion

Abstract

Keywords

Access to Document

Fingerprint

Cite this